| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 6th, 2004 | 22 | Yes |
Popular Name: Chloroquine diphosphate Chloroquine diphosphate
Find On: PubMed — Wikipedia — Google
CAS Numbers: , 132-73-0 , 50-63-5 , 54-05-7 , [132-73-0] , [50-63-5]
1,4-pentanediamine, N~4~-(7-chloro-4-quinolinyl)-N~1~,N~1~-diethyl-
1,4-pentanediamine, N~4~-(7-chloro-4-quinolinyl)-N~1~,N~1~-diethyl-, phosphate (1:2)
132-73-0; Chloroquine sulfate; D07680; Nivaquine (TN)
4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
50-63-5; Chloroquine diphosphate; Prestwick_867
54-05-7; Chloroquine (USP/INN); D02366
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
Aralen; Artrichin; Bemaphate; Capquin; Nivaquine B; Resoquine; Reumachlor; Sanoquin
bis(phosphoric acid); {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
Chloraquine;Chlorochine;Chloroquina;Chloroquinium;Chlorquin;Clorochina
Chloroquin sulfate; Chloroquine sulphate; Chlorquine sulfate
Chloroquine Bis-Phosphoric Acid
CHLOROQUINE DIPHOSPHATE CRYSTALLINE
Chloroquine Hydrochloride (FDA
Chloroquine phosphate, Antibiotic for Culture Media Use Only
chloroquine; chloroquinum; cloroquina
FDA); Chloroquine Phosphate (BAN
GNF-Pf-4216; NSC-187208; TCMDC-123988
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-dimethyl-1,4-pentanediamine diphosphate salt
N4-(7-Chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
N~4~-(7-chloroquinolin-4-yl)-N~1~,N~1~-diethylpentane-1,4-diamine
N~4~-(7-chloroquinolin-4-yl)-N~1~,N~1~-diethylpentane-1,4-diamine bis(phosphate)
Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-
USP); Chloroquine Phosphate (BAN
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 5.01 | 10.55 | -81.59 | 3 | 3 | 2 | 31 | 321.896 | 8 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| Molecular_Solubility | 5.857 | Bitter DB |
| ALOGPS_SOLUBILITY | 1.75e-02 g/l | DrugBank-approved |
| MP | 198 - 200 | Enamine Building Blocks |
| MP | 198...200 | Enamine Building Blocks |
| mp | 200 | MolMall (formerly Molecular Diversity Preservation International) |
| mp | 24 | MolMall (formerly Molecular Diversity Preservation International) |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| Purity | 95% | Fluorochem |
| Indications | Antimalarial | KeyOrganics Bioactives |
| therap | antimalarial, antiamebic, antirheumatic, intercalating agent | MicroSource Spectrum |
| Therapy | Antimalarial; anti-amoebic; anti-inflammatory; bind strongly to double-stranded DNA | SMDC MicroSource |
| UniProt Database Links | CRTP1_DICDI; CRTP2_DICDI; CRTP3_DICDI; CRT_PLABE; CRT_PLACH; CRT_PLAF7; CRT_PLAFA; CRT_PLAKN; CRT_PLAVS; CRT_PLAYO; CRT_THEAN; GST_PLAFA; MDR_PLAFF; MRGA3_MOUSE; MRGX1_HUMAN; S22AI_HUMAN; S22AI_MOUSE; S22AI_RAT; TPO4_YEAST; YAP4_YEAST | ChEBI |
| PUBCHEM_PATENT_ID | EP0208576A1; EP0305756A1; EP0305756B1; EP0436129A1; EP0436129B1; EP0731695A1; EP0731695B1; EP0879605A3; EP0914820A1; EP1046394A2; EP1053030A2; US4151281; US4753984; US4948236; US5009819; US5273757; US5728680; US5770220; US5770576; US5807830; US5811399; US | IBM Patent Data |
| Patent Database Links | EP0965583; EP0965584; EP1374867; EP1634607; EP1649857; EP1754472; EP1759700; EP1815846; EP1829527; EP1829528; EP1829534; EP1832283; EP1832657; EP1889847; EP1894559; EP1990048; GB2373247; US2001036927; US2002025920; US2002107266; US2004254182; US2005070552 | ChEBI |
| Target | Others | Selleck Chemicals |
| Reactome Database Links | REACT_22432 | ChEBI |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| HRP1-1-E | Histidine-rich Protein (cluster #1 Of 1), Eukaryotic | Eukaryotes | 400 | 0.41 | Binding ≤ 10μM |
| KCNH2-5-E | HERG (cluster #5 Of 5), Eukaryotic | Eukaryotes | 2512 | 0.36 | Binding ≤ 10μM |
| NQO2-1-E | Quinone Reductase 2 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 1500 | 0.37 | Binding ≤ 10μM |
| PRIO-1-E | Prion Protein (cluster #1 Of 1), Eukaryotic | Eukaryotes | 4000 | 0.34 | Binding ≤ 10μM |
| HRP1-1-E | Histidine-rich Protein (cluster #1 Of 1), Eukaryotic | Eukaryotes | 77 | 0.45 | Functional ≤ 10μM |
| Z100275-1-O | Hemozoin (cluster #1 Of 1), Other | Other | 400 | 0.41 | Binding ≤ 10μM |
| Z100275-1-O | Hemozoin (cluster #1 Of 1), Other | Other | 77 | 0.45 | Functional ≤ 10μM |
| Z100498-2-O | Hepatocytes (cluster #2 Of 2), Other | Other | 1900 | 0.36 | Functional ≤ 10μM |
| Z101682-1-O | BK Polyomavirus (cluster #1 Of 2), Other | Other | 1700 | 0.37 | Functional ≤ 10μM |
| Z102013-2-O | Plasmodium Malariae (cluster #2 Of 2), Other | Other | 14 | 0.50 | Functional ≤ 10μM |
| Z102015-1-O | Plasmodium Vivax (cluster #1 Of 1), Other | Other | 90 | 0.45 | Functional ≤ 10μM |
| Z50136-2-O | Plasmodium Falciparum (isolate FcB1 / Columbia) (cluster #2 Of 3), Other | Other | 167 | 0.43 | Functional ≤ 10μM |
| Z50424-2-O | Cryptosporidium Parvum (cluster #2 Of 2), Other | Other | 27 | 0.48 | Functional ≤ 10μM |
| Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 100 | 0.45 | Functional ≤ 10μM |
| Z50426-9-O | Plasmodium Falciparum (isolate K1 / Thailand) (cluster #9 Of 9), Other | Other | 900 | 0.38 | Functional ≤ 10μM |
| Z50468-2-O | Giardia Intestinalis (cluster #2 Of 4), Other | Other | 401 | 0.41 | Functional ≤ 10μM |
| Z50473-4-O | Plasmodium Berghei (cluster #4 Of 5), Other | Other | 72 | 0.45 | Functional ≤ 10μM |
| Z50474-1-O | Plasmodium Yoelii (cluster #1 Of 1), Other | Other | 106 | 0.44 | Functional ≤ 10μM |
| Z80136-1-O | FM3A (Breast Carcinoma Cells) (cluster #1 Of 6), Other | Other | 0 | 0.00 | Functional ≤ 10μM |
| Z80682-2-O | A549 (Lung Carcinoma Cells) (cluster #2 Of 11), Other | Other | 40 | 0.47 | Functional ≤ 10μM |
| Z81138-1-O | ScN2a (Scrapie-infected Neuroblastoma Cells) (cluster #1 Of 3), Other | Other | 4000 | 0.34 | Functional ≤ 10μM |
| Z81247-1-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #1 Of 9), Other | Other | 9670 | 0.32 | Functional ≤ 10μM |
| Z100081-2-O | PBMC (Peripheral Blood Mononuclear Cells) (cluster #2 Of 2), Other | Other | 5100 | 0.34 | ADME/T ≤ 10μM |
| Z80186-3-O | K562 (Erythroleukemia Cells) (cluster #3 Of 3), Other | Other | 32 | 0.48 | ADME/T ≤ 10μM |
| Z80291-2-O | MRC5 (Embryonic Lung Fibroblast Cells) (cluster #2 Of 3), Other | Other | 64 | 0.46 | ADME/T ≤ 10μM |
| Z81020-1-O | HepG2 (Hepatoblastoma Cells) (cluster #1 Of 1), Other | Other | 8300 | 0.32 | ADME/T ≤ 10μM |
| Z81115-1-O | KB (Squamous Cell Carcinoma) (cluster #1 Of 3), Other | Other | 600 | 0.40 | ADME/T ≤ 10μM |
| Z81135-5-O | L6 (Skeletal Muscle Myoblast Cells) (cluster #5 Of 6), Other | Other | 7700 | 0.33 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| Z100275 | Z100275 | Hemozoin | 400 | 0.41 | Binding ≤ 1μM |
| HRP1_PLAFA | P05227 | Histidine-rich Protein, Plafa | 400 | 0.41 | Binding ≤ 1μM |
| Z100275 | Z100275 | Hemozoin | 400 | 0.41 | Binding ≤ 10μM |
| KCNH2_HUMAN | Q12809 | HERG, Human | 2500 | 0.36 | Binding ≤ 10μM |
| HRP1_PLAFA | P05227 | Histidine-rich Protein, Plafa | 400 | 0.41 | Binding ≤ 10μM |
| PRIO_HUMAN | P04156 | Prion Protein, Human | 4000 | 0.34 | Binding ≤ 10μM |
| NQO2_HUMAN | P16083 | Quinone Reductase 2, Human | 1500 | 0.37 | Binding ≤ 10μM |
| Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 40 | 0.47 | Functional ≤ 10μM |
| Z101682 | Z101682 | BK Polyomavirus | 1700 | 0.37 | Functional ≤ 10μM |
| Z50424 | Z50424 | Cryptosporidium Parvum | 27 | 0.48 | Functional ≤ 10μM |
| Z80136 | Z80136 | FM3A (Breast Carcinoma Cells) | 0.1 | 0.64 | Functional ≤ 10μM |
| Z50468 | Z50468 | Giardia Intestinalis | 401 | 0.41 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 9665 | 0.32 | Functional ≤ 10μM |
| Z100275 | Z100275 | Hemozoin | 76.5 | 0.45 | Functional ≤ 10μM |
| Z100498 | Z100498 | Hepatocytes | 1900 | 0.36 | Functional ≤ 10μM |
| HRP1_PLAFA | P05227 | Histidine-rich Protein, Plafa | 76.5 | 0.45 | Functional ≤ 10μM |
| Z50473 | Z50473 | Plasmodium Berghei | 72 | 0.45 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 223 | 0.42 | Functional ≤ 10μM |
| Z50136 | Z50136 | Plasmodium Falciparum (isolate FcB1 / Columbia) | 105.3 | 0.44 | Functional ≤ 10μM |
| Z50426 | Z50426 | Plasmodium Falciparum (isolate K1 / Thailand) | 10 | 0.51 | Functional ≤ 10μM |
| Z102013 | Z102013 | Plasmodium Malariae | 127.9 | 0.44 | Functional ≤ 10μM |
| Z102015 | Z102015 | Plasmodium Vivax | 11.9 | 0.50 | Functional ≤ 10μM |
| Z50474 | Z50474 | Plasmodium Yoelii | 106 | 0.44 | Functional ≤ 10μM |
| Z81138 | Z81138 | ScN2a (Scrapie-infected Neuroblastoma Cells) | 4000 | 0.34 | Functional ≤ 10μM |
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 8300 | 0.32 | ADME/T ≤ 10μM |
| Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 31.828 | 0.48 | ADME/T ≤ 10μM |
| Z81115 | Z81115 | KB (Squamous Cell Carcinoma) | 600 | 0.40 | ADME/T ≤ 10μM |
| Z81135 | Z81135 | L6 (Skeletal Muscle Myoblast Cells) | 188.5 | 0.43 | ADME/T ≤ 10μM |
| Z80291 | Z80291 | MRC5 (Embryonic Lung Fibroblast Cells) | 64 | 0.46 | ADME/T ≤ 10μM |
| Z100081 | Z100081 | PBMC (Peripheral Blood Mononuclear Cells) | 5100 | 0.34 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Organic cation transport |
| Description | Species |
|---|---|
| NCAM1 interactions | |
| Voltage gated Potassium channels |
